FindTrial
Sign In

Semaglutide 2.4 mg

DRUG7 trials

Sponsors

Novo Nordisk A/S, Children's Hospital Los Angeles, Emma Svennberg

Conditions

Atrial Fibrillation (AF)Diabetes Mellitus, Type 2Metabolic and Bariatric SurgeryObesityObesity & OverweightOverweightPediatric ObesitySemaglutide

Phase 2

Research Study to Look at How Well Cagrilintide Together With Semaglutide Works in People With Type 2 Diabetes
CompletedNCT04982575
Novo Nordisk A/SDiabetes Mellitus, Type 2
Start: 2021-08-02End: 2022-07-07Updated: 2025-12-23

Phase 3

Research Study Investigating How Well Semaglutide Works in People With Type 2 Diabetes Suffering From Overweight or Obesity
CompletedNCT03552757
Novo Nordisk A/SObesity, Overweight
Start: 2018-06-04End: 2020-05-01Updated: 2021-11-09
Research Study Investigating How Well Semaglutide Works in People From Thailand and South Korea Living With Obesity
CompletedNCT04998136
Novo Nordisk A/SObesity
Start: 2022-08-15End: 2023-11-20Updated: 2025-12-30
Research Study Looking at How Well Semaglutide Works in People Living With Obesity and Prediabetes
CompletedNCT05040971
Novo Nordisk A/SObesity
Start: 2021-09-06End: 2023-07-14Updated: 2026-01-29
Research Study Looking at How Well Semaglutide Works in People Suffering From Obesity and Knee Osteoarthritis
CompletedNCT05064735
Novo Nordisk A/SObesity
Start: 2021-10-01End: 2023-09-08Updated: 2025-11-17
Early Re-Initiation of Semaglutide Post Sleeve Gastrectomy in Youth
Not yet recruitingNCT06934655
Children's Hospital Los AngelesMetabolic and Bariatric Surgery, Pediatric Obesity, Semaglutide
Start: 2026-06-01End: 2033-11-01Target: 150Updated: 2026-03-17

Phase 4

Waiting on Atrial Fibrillation Intervention Therapy (WAIT) Study
Not yet recruitingNCT07275697
Emma SvennbergAtrial Fibrillation (AF), Obesity & Overweight
Start: 2025-12-15End: 2028-12-30Target: 200Updated: 2025-12-10

Related Papers

Once-weekly semaglutide 2·4 mg in an Asian population with obesity, defined as BMI ≥25 kg/m<sup>2</sup>, in South Korea and Thailand (STEP 11): a randomised, double-blind, placebo-controlled, phase 3 trial.
2025-08-153 citations
Proteomic signatures reflect effects of semaglutide treatment for MASH.
2025-07-22
Psychiatric Safety of Semaglutide for Weight Management in People Without Known Major Psychopathology: Post Hoc Analysis of the STEP 1, 2, 3, and 5 Trials.
2024-11-0149 citations
Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis
New England Journal of Medicine2024-10-30230 citations
Efficacy and safety of once-weekly semaglutide 2·4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial.
2024-07-2970 citations
Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial.
2023-06-23186 citations
53-OR: Efficacy and Safety of Coadministered s.c. Semaglutide and s.c. Cagrilintide in Type 2 Diabetes
Diabetes2023-06-23
54-OR: Effect of Coadministered s.c. Semaglutide and s.c. Cagrilintide on Glycemic Levels Measured by CGM
Diabetes2023-06-20
Effects of Semaglutide on Albuminuria and Kidney Function in People With Overweight or Obesity With or Without Type 2 Diabetes: Exploratory Analysis From the STEP 1, 2, and 3 Trials
Diabetes Care2023-02-1784 citations
Abstract 10: Efficacy and safety of semaglutide 2.4 mg once- weekly in adults with overweight or obesity and type 2 diabetes (STEP 2)
Indian Journal of Endocrinology and Metabolism2022-03-01
Confirmatory psychometric evaluations of the Impact of Weight on Quality of Life–Lite Clinical Trials Version (<scp>IWQOL‐Lite‐CT</scp>)
Clinical Obesity2021-07-2219 citations
83-OR: Influence of Baseline Characteristics on Weight Loss with Semaglutide 2.4 mg in Adults with Overweight/Obesity and Type 2 Diabetes (STEP 2)
Diabetes2021-06-014 citations
85-OR: Semaglutide 2.4 mg Improves Patient Reported Outcome Measures of Physical Functioning in Adults with Overweight/Obesity and Type 2 Diabetes in the STEP 2 Trial
Diabetes2021-06-013 citations
84-OR: Semaglutide 2.4 mg Improves Health-Related Quality of Life in Adults with Overweight/Obesity and Type 2 Diabetes in the STEP 2 Trial
Diabetes2021-06-012 citations
Efficacy and Safety of Semaglutide 2.4 MG Once-Weekly in Adults With Overweight or Obesity and Type 2 Diabetes (STEP 2)
Journal of the Endocrine Society2021-05-013 citations
Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.
2021-03-02839 citations
Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5
Obesity2020-05-22265 citations